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Abstract
Background: Targeting protein for Xenopus kinesin-like protein 2 (TPX2) is a microtubule-associated protein
required for microtubule formation in human cells. Several studies have demonstrated that TPX2 is overexpressed
in multiple tumor types and promotes tumor growth and metastasis. However, there have been few reports
regarding its role in gastric cancer. In this study, we evaluated TPX2 expression and investigated its correlations
with gastric cancer clinicopathological features and prognosis.
Methods: Tumor samples were obtained from 290 patients with gastric adenocarcinoma who had undergone
gastrectomy. The expression of TPX2 protein was examined using immunohistochemical staining. TPX2 messenger
RNA (mRNA) levels were evaluated using real-time quantitative reverse transcription PCR in 19 of the gastric cancer
tumors and adjacent normal tissues.
Results: The mRNA levels of TPX2 were significantly higher in gastric cancer tissues than in matched adjacent
normal tissues (p = 0.004). In the immunohistochemical analysis, TPX2 overexpression was found in 123 (42.4%)
of 290 patients. High TPX2 expression was positively associated with age, type of histology, depth of tumor, lymph
node metastasis, stage, and remote metastasis or recurrence. High TPX2 expression was significantly associated
with poorer disease-specific survival (p = 0.004) and relapse-free interval (p = 0.013).
Conclusions: Our results indicated that high TPX2 expression was associated with tumor progression and poor
survival in gastric cancer.
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Background
Although the mortality rate of gastric cancer has been
declining for several decades, this disease remains one of
the most common cancers [1]. Surgery is the main
treatment for patients with localized disease, but even
after macroscopic complete removal, many patients with
advanced disease experience recurrence [2]. While com-
bination chemotherapy regimens have been developed,
overall survival ranges from 10 to 14 months in patients
with unresectable or metastatic gastric cancer [3–5].
Therefore, the identification of prognostic biomarkers
may contribute towards improving treatment strategies
for gastric cancer patients.
Chromosomal instability and subsequent aneuploidy can
promote tumor development [6]. Levels of targeting protein
for Xenopus kinesin-like protein 2 (TPX2) were found to
correlate with chromosomal instability [7]. High expression
of TPX2 induces the amplification of centrosomes and
leads to DNA polyploidy [8]. TPX2 is a microtubule-
associated protein that is encoded by a gene located on
human chromosome band 20q11.1. Its expression is tightly
regulated by the cell cycle, and this protein is detected dur-
ing the G1-S stage and disappears after the completion of
mitosis. TPX2 is located in the nucleus during S-phase and
G2 and at the spindle poles during mitosis. As a critical
regulator of mitosis, TPX2 cooperates with Aurora-A
kinase and Eg5 kinesin to control microtubule assembly and
spindle stability. TPX2 is required for the formation of nor-
mal bipolar spindles and chromosome segregation [9, 10].* Correspondence: m-inokuchi.srg2@tmd.ac.jp1Department of Gastrointestinal Surgery, Tokyo Medical and Dental
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Overexpression of TPX2 has been reported in many
types of tumors, including those from lung, hepatic,
colon, pancreatic, salivary gland, and cervical cancers
[11–18]. Moreover, TPX2 expression is a marker of
worse tumor prognosis in several cancers [11–14].
These observations suggest that TPX2 plays a role in
the oncogenesis of at least some malignancies. Neverthe-
less, there have been few studies that have reported inves-
tigation of the expression of TPX2 in gastric cancer.
Therefore, in this study, we evaluated the expression of
TPX2 in surgically resected specimens of gastric cancer
and analyzed the association between TPX2 expression,
clinicopathological factors, and survival.
Methods
Patients
Between January 2003 and December 2008, 290 patients
underwent gastrectomy in the Department of Gastric
Surgery of Tokyo Medical and Dental University. All
patients were given sufficient explanation of the study,
and written informed consent was obtained. This study
was conducted in accordance with the Declaration of
Helsinki and was approved by the Institutional Review
Board of Tokyo Medical and Dental University.
Each tumor was classified according to the tumor-
node-metastasis classification system recommended by
the Union for International Cancer Control. Follow-up
surveillance was performed every 3 to 6 months with
computed tomography, abdominal ultrasonography, and
tumor marker analysis. Patients with distant metastatic
or recurrent disease received chemotherapy with S-1
(oral fluoropyrimidine consisting of tegafur, gimeracil,
and oteracil potassium; Taiho Co, Tokyo, Japan) alone or
combined chemotherapy. The median follow-up period
was 62 months (range, 2–111 months). During follow-
up, a total of 99 patients (34%) died as a result of their
disease, 84 (29%) had recurrent disease, and 15 (5%) died
of other causes.
RNA extraction and cDNA synthesis
Immediately after surgery, small samples of gastric
cancer tissue and adjacent normal tissue were collected,
individually placed in RNA stabilization reagent (RNAla-
ter; Qiagen, Valencia, CA, USA) and stored at −80 °C
until analysis. Total RNA was extracted from each
sample using the RNeasy Mini Kit (Qiagen) according
to the manufacturer’s protocol. The concentration of total
RNA was determined by absorption measurements at 260
and 280 nm using a UV spectrophotometer (Beckman
Counter; Beckman Coulter, Brea, CA, USA). For comple-
mentary DNA (cDNA) synthesis, 10 μg of total RNA from
each sample was reverse-transcribed into cDNA using the
High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA, USA) according to the
manufacturer’s protocol.
Real-time quantitative reverse transcription PCR
Expression levels of TPX2 and the gene for β-actin,
which served as the endogenous control, were deter-
mined by real-time quantitative reverse transcription
PCR (qRT-PCR) using the 7300 Real-Time PCR System
(Applied Biosystems). TaqMan gene expression assays were
purchased from Applied Biosystems (Hs00201616_m1).
The PCR reaction was carried out using TaqMan Universal
Master Mix II (Applied Biosystems) with 1 μl of cDNA in
a 24-μl final reaction volume. Thermal cycling conditions
were as follows: 2 min at 50 °C, 10 min at 95 °C, 40 cycles
each of 15-s denaturation at 95 °C, and 1 min of annealing
at 60 °C. The cDNA synthesized by the gastric cancer cell
line MNK 45 was used for calibration. Each sample was
run in duplicate for both the target gene and the endogen-
ous control gene. The amount of TPX2, normalized to the
endogenous control and relative to the calibration samples,
was calculated by the comparative threshold cycle (Ct)
method using Relative Quantification Study Software ver-
sion 1.4 on the 7300 Sequence Detection System (Applied
Biosystems).
Immunohistochemical analysis of TPX2
Immunostaining was carried out with a peroxidase-
labeled polymer conjugated to secondary antibodies
(Histofine Simple Stain Max PO (MULTI), Nichirei Co.,
Tokyo, Japan). A monoclonal mouse antibody against
TPX2 (sc-376812) was purchased from Santa Cruz
Biotechnology, Inc. (Dallas, TX, USA.). All of the ori-
ginal hematoxylin and eosin-stained slides of the surgical
specimens were reviewed if available, and representative
paraffin blocks for each case were selected for immuno-
histochemistry. Four-micrometer-thick sections were cut
from formalin-fixed, paraffin-embedded tissue blocks.
After deparaffinization and rehydration, antigen retrieval
treatment was conducted for 25 min in 1 × TE (1 × Tris-
EDTA, pH 8.0) at 98 °C in a microwave processor (MI-77;
AZUMAYA, Tokyo, Japan). Endogenous peroxidase activ-
ity was quenched by a 15-min incubation in a solution of
3% hydrogen peroxide in 100% methanol. After washing
with phosphate-buffered saline (PBS), the slides were in-
cubated with the primary monoclonal antibody against
TPX2 (dilution 1:50) for 30 min at room temperature and
then overnight (16 h) at 4 °C. The slides were washed
three times with 0.1% Tween 20/PBS and were then incu-
bated with Simple Stain Max PO (MULTI) for 30 min at
room temperature. After three additional washes, 3,3’-di-
aminobenzidine tetrahydrochloride solution (Histofine
Simple Stain DAB Solution; Nichirei Co., Tokyo, Japan)
was applied to the slides, which were then counterstained
with Mayer’s hematoxylin (Wako, Tokyo, Japan). Gastric
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cancer tissue from participants in this study that were
strongly positive for TPX2 served as positive controls.
Evaluation of immunohistochemistry for TPX2
In the tissue samples stained for TPX2, slides were
considered positively stained when tumor cell nuclei
were stained a darker brown than the background level
of staining, regardless of intensity. TPX2 staining was
graded as high (≥5% of tumor cells stained) or low (<5%
of tumor cells stained). We stained representative cross-
sectional slices of tumor tissue and counted at least
five fields within most stained sections. The stained
slides were evaluated by two independent observers
(CT and YT) who were blinded to each patient’s
Fig. 1 Targeting protein for Xenopus kinesin-like protein 2 (TPX2) mRNA expression in gastric cancerous and adjacent normal tissues. The median
TPX2 mRNA level was significantly higher in gastric cancer than in the adjacent normal tissue in 19 patients (p = 0.004)
Fig. 2 Representative photomicrographs of immunostaining for targeting protein for Xenopus kinesin-like protein 2 (TPX2), demonstrating
a negative staining in normal gastric epithelium, b negative staining in primary gastric carcinoma, c positive staining graded as low (<5% of
tumor cells stained), and d positive staining graded as high (≥5% of tumor cells stained). TPX2 protein was mainly localized within the nuclei
of tumor cells. Images were captured at ×200 magnification
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prognosis. Any disagreements between the two ob-
servers were resolved by reassessment and consensus.
Statistical analysis
The messenger RNA (mRNA) expression of TPX2 in gas-
tric cancer tissues and matched adjacent normal tissues
was compared using paired t tests. The χ2 test and the
Mann-Whitney U test were used to analyze the associ-
ation between TPX2 protein expression and clinicopatho-
logical factors. Kaplan-Meier curves were compared using
a log-rank test for univariate analysis of disease-specific
survival (DSS) and relapse-free interval (RFI). For the RFI
analysis, 25 stage IV patients were excluded. In all
analyses, IBM SPSS Statistics Software version 22 (IBM,
Armonk, NY, USA) was used, and p values <0.05 were
considered significant.
Results
mRNA expression of TPX2
Initially, we assayed TPX2 mRNA levels in a retrospect-
ive cohort of 19 gastric cancer tissues and matched
adjacent normal tissues using qRT-PCR. In this cohort,
the median TPX2 mRNA level was significantly higher
in gastric cancer tissues than in matched adjacent normal
tissues (p = 0.004; Fig. 1).
Immunohistochemistry for TPX2 expression
Expression of the TPX2 protein was assessed by immu-
nohistochemical staining of gastric cancer tissue samples
from 290 patients. Of these samples, 123 (42.4%) were
classified as having high TPX2 expression (≥5% of tumor
cells stained). TPX2 expression was mainly observed in
the nuclei of tumor cells, with no expression observed in
the nuclei of cells in normal tissue (Fig. 2). Weak expres-
sion was observed in the cytoplasm of some tumor cells.
Relationship between TPX2 and clinicopathological factors
High expression of TPX2 was significantly associated
with the patient’s age (<65 vs. ≥65, p < 0.001), type of
histology (differentiated vs. undifferentiated, p = 0.002),
depth of tumor (T1 vs. T2 vs. T3 vs. T4, <0.001), lymph
node metastasis (N0 vs. N1 vs. N2 vs. N3, p < 0.001), stage
(I vs. II vs. III vs. IV, p < 0.001), and remote metastasis or
recurrence (presence vs. absence, p = 0.02; Table 1).
Relationship between TPX2 and survival
High expression of TPX2 was associated with poorer
DSS (p = 0.004) and RFI (p = 0.013) by univariate
analysis. In patients with positive expression of
TPX2, the 5-year DSS was 65.9% and the RFI was
69.9%; in patients with negative expression of TPX2,
these values were 78.1 and 82.8%, respectively (Figs. 3
and 4).
After adjustment for significant prognostic factors
(age, histopathology, tumor location, depth of invasion,
lymph node involvement), the multivariate analysis of
clinicopathological features affecting DSS indicated
that independent prognostic factors were depth of
tumor invasion (hazard ratio (HR) 7.7, 95% CI 2.7 to
21.6, p < 0.001) and lymph node metastasis (HR 6.4,
95% CI 3.1 to 13.2, p < 0.001; Table 2). After adjust-
ment for the same significant prognostic factors,
multivariate analysis of clinicopathological features
affecting RFS indicated that independent prognostic
factors were tumor main location (HR 1.9, 95% CI
1.1 to 3.3, p = 0.02), depth of tumor invasion (HR 6.0,
Table 1 Relationship between expression of TPX2 and patient
clinicopathological factors
TPX2 expression
n Low (n = 167) High (n = 123) p value
Gender
Male 219 127 92
Female 71 40 31 0.807
Age
<65 129 88 41
≥65 161 79 82 0.001
Pathological type
Undifferentiated 158 104 54
Differentiated 132 63 69 0.002
Main location
Middle or lower 233 135 98
Upper 57 32 25 0.805
Depth of invasion
T1 120 83 37
T2 37 22 15
T3 49 24 25
T4 84 38 46 <0.001
LN metastasis
N0 149 104 45
N1 44 26 18
N2 39 12 27
N3 58 25 33 <0.001
Stage
I 139 98 41
II 51 26 25
III 75 30 45
IV 25 13 12 <0.001
Distant metastasis or recurrence
Negative 205 127 78
Positive 85 40 45 0.020
TPX2 targeting protein for Xenopus kinesin-like protein 2, LN lymph node
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95% CI 2.1 to 17.1, p = 0.001), and lymph node me-
tastasis (HR 6.7, 95% CI 3.0 to 15.3, p < 0.001;
Table 3). High TPX2 expression was not an inde-
pendent prognostic factor for either DSS or RFS.
Comparison of Kaplan-Meier curves of the DSS of
patients with low and high TPX2 expression after
recurrence by using the log-rank test showed no
significant difference between the DSS of these two
groups (p = 0.52; Fig. 5).
Discussion
In this study, we used a large set of surgically resected
gastric cancer tissue samples to assess the expression of
TPX2 at the protein level. Our results indicated that
Fig. 3 Kaplan-Meier curves for the disease-specific survival (DSS) of patients with targeting protein for Xenopus kinesin-like protein 2 (TPX2)
expression. Patients with high TPX2 protein expression (n = 123) had significantly poorer DSS than those with low TPX2 expression
(n = 167; p = 0.004)
Fig. 4 Kaplan-Meier curves for the relapse-free interval (RFI) of patients with targeting protein for Xenopus kinesin-like protein 2 (TPX2) expression.
Patients with high TPX2 protein expression (n = 123) had significantly poorer RFI than those with low TPX2 expression (n = 167; p = 0.013)
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high expression of TPX2 may play a critical role in
tumor progression, metastasis, and survival in gastric
cancer.
TPX2 expression in samples of human gastric cancer
has been investigated in one previous study [19].
Although that study differed from ours in having a
smaller sample size and different evaluation of the
immunohistochemical results, their findings were
similar to those of our study. Those authors reported
that overexpression of TPX2 was related to advanced
stages and poor survival. Moreover, they further reported
that TPX2-siRNA suppressed tumor cell epithelial-
mesenchymal transition in gastric cancer cell lines [19].
A number of studies have examined the relationship
between TPX2 and human malignancies. TPX2 is highly
expressed at both the mRNA and protein level in many
types of cancers, including lung, hepatic, colon, pan-
creatic, salivary gland, and cervical cancers [11–18].
Using immunostaining, multiple studies reported that
TPX2 is mainly localized within the nuclei of cancer
cells [11–18]. TPX2 expression detected by immuno-
histochemical analysis was associated with depth of
tumor, lymph node metastasis, and remote metastasis
in colon cancer [13]. TPX2 expression analyzed by
immunohistochemistry was associated with poor pa-
tient survival in many types of cancer [11–14]. TPX2
is an independent prognostic indicator for poor pa-
tient survival in hepatic cancer [14]. In colon cancer,
TPX2 is strongly associated with the progression of
colorectal adenoma to carcinoma [16].
TPX2 has been identified as a microtubule-associated
protein that is required for bipolar spindle assembly.
TPX2 recruits Aurora-A kinase to microtubules and
drives the activation of this kinase during mitosis.
TPX2-Aurora-A binding is promoted by an active
Ran-GTP signaling pathway [9, 10]. The critical role
of TPX2 in mitosis is supported by several studies. In
HeLa cells, treatment with TPX2-siRNA caused de-
fects in microtubule organization during mitosis, with
the consequence that microtubule asters could not be
formed and the spindle could not be assembled [8].
In mouse embryonic fibroblasts, TPX2-siRNA-treated
embryos arrested at the morula stage with defective
mitotic spindles [20]. Moreover, TPX2-siRNA treatment
Table 2 Prognostic factors for disease-specific survival (DSS)
in univariable and multivariable Cox proportional hazards
regression models
Univariate (log-rank) Multivariate






≥65 68.1 0.025 1.42 0.90 to 2.26 0.136
Pathological type
Differentiated 82.0 1
Undifferentiated 65.4 0.004 1.32 0.82 to 2.12 0.253
Main location
Middle or lower 76.1 1
Upper 59.7 0.026 1.52 0.94 to 2.47 0.089
Depth of invasion
T1 97.4 1
T2-T4 56.0 <0.001 7.66 2.71 to 21.6 <0.001
LN metastasis
Negative 94.5 1
Positive 50.0 <0.001 6.40 3.10 to 13.2 <0.001
TPX2
Low 78.1 1
High 65.9 0.004 1.05 0.66 to 2.26 0.840
DSS disease-free survival, TPX2 targeting protein for Xenopus kinesin-like
protein 2, LN lymph node
Table 3 Prognostic factors for relapse-free interval (RFI) in
univariable and multivariable Cox proportional hazards
regression models
Univariate (log-rank) Multivariate









Undifferentiated 70.5 0.004 1.46 0.82 to 2.57 0.196
Main location
Middle or lower 81.4 1
Upper 60.9 0.003 1.93 1.12 to 3.31 0.017
Depth of invasion
T1 96.6 1
T2-T4 61.7 <0.001 6.01 2.11 to 17.1 0.001
LN metastasis
Negative 95.2 1
Positive 54.7 <0.001 6.72 2.95 to 15.3 <0.001
TPX2
Low 82.8 1
High 69.9 0.013 1.16 0.68 to 1.96 0.590
RFI relapse-free interval, TPX2 targeting protein for Xenopus kinesin-like
protein 2, LN lymph node
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resulted in the generation of tetraploid and aneuploid
cells [20]. These preclinical studies suggest that TPX2
is required for the formation of normal bipolar spin-
dles and normal cell division.
Many studies suggest that decreasing TPX2 levels may
be a beneficial approach for cancer treatment. For in-
stance, TPX2-siRNA decreased the viability and prolifer-
ation capacity of colon, cervical, and hepatic cancer cell
lines [13, 14, 18]. Similarly, TPX2-siRNA induced cell
apoptosis in hepatic cancer cell lines [12]. Moreover, in-
jection of TPX2-siRNA significantly reduced the growth
and weight of already developed xenograft tumors in
nude mice [13–15, 21, 22]. TPX2 plays an important
role in the mechanism of paclitaxel’s activity against can-
cers [23]. Warner et al. suggested that the exposure of
pancreatic cancer cells to TPX2-siRNA plus paclitaxel
results in a synergistic decrease in cell viability [15].
These observations suggest that targeted inactivation of
TPX2 may have therapeutic benefits. However, TPX2
inhibitors have not been developed, and most current
therapies are designed to inhibit its partner, Aurora-A,
using small-molecule kinase inhibitors [24].
Several limitations of this study should be acknowl-
edged. First, gene expression of TPX2 was assessed in
only 19 tissues. However, in the Oncomine database,
high levels of TPX2 mRNA and copy number gain of the
TPX2 gene are shown in some datasets of human gastric
cancers [25]. Further studies are required to assess more
patient samples for TPX2 gene expression and to further
explore its clinical significance. Second, in our evalu-
ation of immunohistochemistry slides, we set the cutoff
point for a positive immunoreactive score at 5% of the
cells. However, studies of other types of cancers have set
the immunoreactivity cutoff point at 10% [11, 17]. In
gastric cancer, there is no consensus for a cutoff point;
furthermore, we observed that few cases displayed stain-
ing in more than 10% of the cells.
Conclusions
We found that high TPX2 expression was associated
with tumor progression and poor survival in gastric
cancer patients. TPX2 may thus play an important role
in tumor progression in gastric cancer.
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